Angiographic predictors of adverse outcomes in the modern interventional era**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by White, Christopher J
EDITORIAL COMMENT
Angiographic Predictors of
Adverse Outcomes in
the Modern Interventional Era*
Christopher J. White, MD, FACC
New Orleans, Louisiana
The development of preprocedural angiographic risk strat-
ification criteria was meaningful in the balloon angioplasty
era (1). Acute ischemic complications consisted of angio-
graphic complications with impairment of epicardial coro-
nary blood flow. The demonstration that these post-
percutaneous coronary intervention (PCI) ischemic
complications were related to the preprocedural angio-
graphic complexity of the lesion allowed operators to risk-
stratify patients. Current practice strategies have made
non-angiographic complications, reflected by rise in creatine
kinase MB fraction (CK-MB) enzyme, the most common
post-PCI adverse event. The clinical impact of these rises in
cardiac enzyme after PCI has been debated, but current
evidence supports their negative prognostic value, particu-
larly for larger increases in CK-MB (2).
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In this issue of the Journal, Ross et al. (3)—using a
modern clinical practice data set and employing stents,
IIb/IIIa glycoprotein platelet receptor antagonists, and
thienopyridines— have identified preprocedural angio-
graphic variables associated with procedural complications
and adverse late outcomes. They studied 4,809 patients
enrolled in the Do Tirofiban and ReoPro Give Similar
Efficacy Outcomes (TARGET) trial (4). Three variables—
intracoronary thrombus, lesion eccentricity, and lesion
length 20 mm—were independently associated with a
composite end point of death, myocardial infarction (MI),
and target vessel revascularization (TVR). Also, left anterior
descending coronary artery (LAD) intervention, restenosis
lesions, and longer lesions were independently associated
with six-month TVR.
A major limitation of the study, acknowledged by the
authors, is that the angiographic lesion assessments were not
subjected to the systematic rigor of core lab analysis. Further
weakening this analysis is the knowledge that coronary
angiography is an unreliable method for identifying both
intracoronary thrombus and lesion eccentricity. Using cor-
onary angioscopy as the gold standard for thrombus iden-
tification, angiography has a high rate of both false-positive
(17%) and false-negative (55%) findings (5). The impreci-
sion with which thrombi are identified by angiography
explains the lack of consensus regarding its importance as an
angiographic risk factor.
When intravascular ultrasound is used as the standard for
determining lesion eccentricity, angiographic imaging has
no better than a random (50%) chance of being correct (6).
However, lesion eccentricity is directly related to lesion
length. The longer the lesion, the more likely it will be
eccentric (6). The third variable, lesion length, is perhaps
more reliably determined because the operator can directly
compare the length of the angioplasty balloon to lesion
length. Lesion length is a surrogate marker for plaque
burden, and plaque burden has been well described as a
predictor of post-PCI ischemic complications after coronary
intervention (7,8).
Although the use of optimal stent deployment strategies
and thienopyridines minimizes the risk of acute vessel
closure that was the bane of balloon angioplasty, stent
placement alone did not lower the risk of post-PCI ischemic
complications (death and MI) in the seminal trials that
demonstrated the superiority of stents over balloon angio-
plasty (9,10). In the Stent Restenosis Study (STRESS),
death and MI occurred in 5.0% of the stent group and 6.5%
of the balloon group. In the Benelux Stent Study Group
(BENESTENT) (9), death and MI occurred in 3.4% of the
stent group and 3.1% of the balloon group. Not until the
trials of IIb/IIIa glycoprotein platelet receptor antagonists
was a benefit in the reduction of acute ischemic complica-
tions seen in the stent trials (11,12). Furthermore, the
reduction of post-PCI CK-MB enzyme elevations with a
IIb/IIIa glycoprotein platelet receptor antagonist is associ-
ated with a late survival benefit documented at a median
follow-up of 4.8 years (range, 3 to 7 years) (13).
The mechanism of post-PCI CK-MB elevation after
coronary interventions is due to either angiographic epicar-
dial coronary complications or impairment of the microcir-
culation (distal embolization or vasoconstriction). Angio-
graphic complications of PCI, such as side-branch
occlusion, are uncommon (5%), leaving impairment of the
microcirculation the most likely etiology for post-PCI
CK-MB elevations. Cardiac magnetic resonance imaging
has shown localized myonecrosis (hyperenhancement) in
patients with elevated post-PCI CK-MB without side-
branch occlusion (14). Further evidence linking impairment
of the coronary microcirculation as the etiology of post-PCI
ischemic complications is shown in work by Gibson et al.
demonstrating that rises in post-PCI CK-MB are related to
reduced myocardial perfusion (TIMI myocardial perfusion)
and not epicardial blood flow (TIMI flow or TIMI frame
count) (15).
Several studies have demonstrated that glycoprotein IIb/
IIIa platelet receptor antagonists have little or no effect in
reducing post-PCI CK-MB rises in patients with angio-
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graphic complications; rather, their major benefit is in
patients without angiographic complications—those with
microcirculation impairment (16,17). To complete the cir-
cle, there is preliminary evidence that glycoprotein IIb/IIIa
platelet receptor antagonists do improve tissue level perfu-
sion (18).
Risk assessment and avoidance of procedural and late
adverse outcomes is a key concern for every interventionalist
when selecting patients for percutaneous therapy. Prepro-
cedural identification of high-risk lesions allow choices to be
made to minimize early and late adverse outcomes. Options
range from not performing an intervention to making
strategic choices to maximize a safe outcome.
To further enhance the safety of PCI, it appears that we
need to protect the microcirculation. The success of distal
emboli protection devices (19) and the failure of glycopro-
tein IIb/IIIa platelet receptor antagonists in reducing post-
PCI complications in saphenous vein grafts implies that the
volume of atheromatous debris can overwhelm the benefi-
cial effect of glycoprotein IIb/IIIa platelet receptor antago-
nists (20). It would appear that the greater the volume of
atheroembolic debris (plaque burden), the less effective are
the glycoprotein IIb/IIIa platelet receptor antagonists.
Therefore, if long lesions reflect increased plaque burden
and increased plaque burden is more likely to result in
atheroembolism to the microcirculation, manifested by
post-PCI CK-MB elevation, then one strategic choice will
be to select an emboli protection device. Likewise, the
baseline angiographic variables indicative of late adverse
events, such as longer lesions, LAD interventions, and
restenosis lesions can be used to select specific technologies,
such as drug-eluting stents, to reduce late TVR. Future
trials will be required to confirm the utility of these
variables, particularly lesion length (plaque burden), and to
determine the efficacy of strategies designed to minimize
both early and late adverse events after percutaneous inter-
vention.
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